ERAP2

Across TCGA pan-cancer cohorts, ERAP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ERAP2 data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ERAP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERAP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

COAD, CCRCC, and PDAC are the cancer types where ERAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.887	1.000	.020	30	view →
CCRCC	DFS	Quartile	II,III,IV	0.555	0.923	.013	8	view →
PDAC	OS	Quartile	II,III,IV	0.892	0.719	.005	6	view →
HNSC	OS	Median	II,III,IV	0.806	0.602	.030	5	view →
GBM	DFS	Median	All	0.644	0.788	<.001	2	view →
LSCC	OS	Median	II,III,IV	0.701	0.872	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ERAP2–COAD (DFS)

Open the COAD breakdown →